Sodium Propionate Supplement and Gut Bacteria in Adults With Crohn's Disease
Tests sodium propionate against sodium butyrate in adults with quiet or mild inflammatory bowel disease.
Plain-language title generated from the registry record
Registry title: Microencapsulated Sodium Propionate in IBD Microbiota Modulation
Key facts
- Where
- Padova, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07883044, who can take part
Where in Italy
- Edoardo V. SavarinoPadova, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Padova
- Trial code
- NCT07883044
- Record updated
- 20 October 2026
- Original description
The goal of this clinical trial is to evaluate whether microencapsulated sodium propionate can modulate the gut microbiota and improve inflammatory and immunological parameters in adult patients with inflammatory bowel disease (IBD) in remission or with mild disease activity. The study will also compare its effects with those of sodium butyrate.Read full original descriptionShow less
Microencapsulated Sodium Propionate: a Potential Ally in Microbiota Modulation for the Treatment of Chronic Inflammatory Bowel Diseases
The goal of this clinical trial is to evaluate whether microencapsulated sodium propionate can modulate the gut microbiota and improve inflammatory and immunological parameters in adult patients with inflammatory bowel disease (IBD) in remission or with mild disease activity. The study will also compare its effects with those of sodium butyrate.
The main questions it aims to answer are:
* Does sodium propionate modify gut microbiota composition and metabolic pathways in patients with IBD? * Does sodium propionate influence inflammatory markers, immune cell balance (Treg/Th17), and quality of life?
Researchers will compare sodium propionate to sodium butyrate to determine whether propionate provides similar or additional benefits in microbiota modulation and inflammation control.
Participants will:
* Take either microencapsulated sodium propionate or sodium butyrate daily for 45 days, followed by a washout period and crossover to the alternate treatment * Provide stool samples for microbiota analysis and blood samples for inflammatory cytokine assessment at predefined time points * Complete quality-of-life questionnaires (IBDQ) during the study period
Inclusion: Confirmed diagnosis of Crohn's disease based on clinical, endoscopic, and histopathological evidence (colonoscopy performed within 2 months prior to enrollment); Disease in remission or with mild clinical activity (Mayo score 0-1), confirmed by clinical, endoscopic, or histopathological findings; Age between 18 and 75 years; Ability to fully participate in all aspects of the clinical study.
Exclusion: Severe disease activity and ulcerative colites diagnosis; Positive stool test for Clostridioides difficile; Pregnancy.